# Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma

> **NCT00001270** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 85 (—)

## Conditions studied

- Breast Neoplasms
- Lymphoma
- Neoplasm Metastasis
- Testicular Neoplasms

## Interventions

- **DRUG:** interleukin-1

## Key facts

- **NCT ID:** NCT00001270
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1991-06
- **Primary completion:** —
- **Final completion:** 2000-03
- **Target enrollment:** 85 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001270, "Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00001270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*